No, MHAN had a couple of products in their pipeline, but the main one was Hedrin, Licensed from a Europe firm in a US JV with MHAN.
They took over another private firm that had 3-4 drugs in their pipeline, but MHAN failed to get further funding and was taken over and R/M in to the current firm, to take the current firm and major products public.
All of the product candidates, about 6-7 of them that MHAN had in late 2011, have obviously been shelved, but could be spun off or sold at some point to raise cash.
Ambition with out knowledge is like ship in dry dock. Going nowhere fast!
Market Data 
Markets 
AI
